Intelligent Bio Solutions lines up $15M private placement tied to FDA clearance
What's the deal? Intelligent Bio SolutionsDealroom has a profile for this one. Try Dealroom → has agreed to a private placement of up to $15 million with a single existing institutional investor, priced at-the-market under Nasdaq rules. The structure delivers $5 million upfront at closing, with additional capital available through tranche warrants.
How it's structured: A $5 million tranche warrant becomes callable by the company after the US Food and Drug Administration grants 510(k) clearance for its Intelligent Fingerprinting Drug Screening System. That ties part of the funding directly to a regulatory milestone.
Why now? The at-the-market pricing lets the company raise capital without a discount to its share price, and the milestone-linked tranche gives it access to more funds as it advances toward FDA clearance.
The signal: At $15 million, the round sits in the 43rd percentile by amount among comparable deals — a modest but structured raise. For a company reliant on a pending regulatory decision, tying capital to that clearance aligns funding with the path to market.
Read more: aktiencheck.de
Image credit: Generated with Gemini
